Ruxolitinib

Ruxolitinib has been studied in 30 papers since 2020: 2 trials and 2 observational studies in people, 17 in animals, 3 in cells, 5 reviews; 17 in the past year. It is an approved medicine. The newest story, Oct 26, 2026: “Ruxolitinib reduces retinal blood vessel leakage in rats”.

InterventionApproved 2011

30 papers study it6 more mention it49 findingsUpdated

PubChemChEBIMeSH

Research on it is growing 173% faster than aging research as a whole: 11 papers in the latest year counted

2 new papers in 30 daysSee all 36 papers on ruxolitinib

At a glance

Ruxolitinib extends lifespan in dystrophin/utrophin-deficient mice in one study; independent labs also report reduced senescence in human cells and reduced SASP. Cell studies also report senolytic resistance in senescent human preadipocytes. Its registered trials concern uses other than aging, and the human paper declares ties to developers Incyte and Novartis.

49 findings in 22 papers from 2020 to 2026, 6 of them since May 2026

The findings reach people, from one lab or study; independent labs found the same change in cells and mice. 16 independent labs in 5 countries; 348 trials, none about aging, 54 with no results posted.

“mean JAK2V617F allele burden declined from baseline (ruxolitinib, 66.1%; crossover, 69.5%) through week 208 (41.4%; 37.1%)”
Ruxolitinib treatment in patients with polycythemia vera reduces JAK2 variant allele frequency and improves symptom burden and hematocrit controlTherapeutic advances in hematology2026doi:10.1177/20406207261425083

None of its findings points the other way.

Cells and mice: replicated by independent labs. Humans: a single group. Worms or flies: nothing yet.
  • 16 independent labs in 5 countries
  • 348 trials, none about aging, 54 with no results posted
  • Funders: National Institutes of Health and others
  • 11 of 48 findings with company ties
  • Human trial2
  • Humans2
  • Animals17
  • Cells3

Studies in people

1 study gave ruxolitinib to people and measured what changed.

What changedDesignPeopleSource

up: Improves hematocrit control62.0% vs 18.2%

down: Decreases symptom burden

down: Decreases JAK2V617F allele burdenfrom 66.1% to 41.4%

Randomized trial208 weeks371 peoplePatients with polycythemia vera enrolled in RESPONSE and RESPONSE-2Therapeutic advances in hematology, Mar 24, 2026

What did studies of ruxolitinib find?

39

Studies of ruxolitinib measured 39 outcomes; the most studied are cellular senescence (6 studies) and senescence-associated secretory phenotype (SASP) (2).

Cellular senescence

downin human cells3downin rat cells2downin animals1downin mice1

6 studies
  1. Ruxolitinib inhibits cellular senescence in IFN-γ-stimulated human MuSCs.

    Cellsin IFN-γ-stimulated human MuSCs

  2. Ruxolitinib decreases cellular senescence in replicative senescent NPCs.

    Cellsin replicative senescent NPCsnucleus pulposus

  3. Ruxolitinib decreases cellular senescence in LPS-induced neonatal rat cardiomyocytes.

    Cellsin LPS-induced neonatal rat cardiomyocytes

  4. Ruxolitinib decreases cellular senescence in septic cardiomyopathy mouse models.

    Animalsin septic cardiomyopathy mouse models

  5. Ruxolitinib decreases cellular senescence (JAKi loaded scaffold).

    AnimalsJAKi loaded scaffold

  6. Ruxolitinib decreases cellular senescence in COPD lung cells.

    Cellsin COPD lung cellslung

  7. Ruxolitinib decreases cellular senescence in human normal fibroblasts expressing progerin.

    Cellsin human normal fibroblasts expressing progerin

More on Cellular senescence

Senescence-associated secretory phenotype (SASP)

downin animals1downin rat cells1

2 studies
  1. Ruxolitinib inhibits senescence-associated secretory phenotype (SASP) in replicative senescent NPCs.

    Cellsin replicative senescent NPCsnucleus pulposus

  2. Ruxolitinib decreases senescence-associated secretory phenotype (SASP) (JAKi loaded scaffold).

    AnimalsJAKi loaded scaffold

More on Senescence-associated secretory phenotype (SASP)

JAK2V617F allele burden

downin humans1

1 study
  1. Ruxolitinib decreases JAK2V617F allele burden in humans (from 66.1% to 41.4%).

    Human trialn = 184

  2. Ruxolitinib decreases JAK2V617F allele burden in patients with hydroxyurea-resistant/intolerant PV (66.1% to 41.4% (ruxolitinib), 69.5% to 37.1% (crossover)).

    Human trialin patients with hydroxyurea-resistant/intolerant PVweek 208n = 371

More on JAK2V617F allele burden

Symptom burden

downin humans1

1 study
  1. Ruxolitinib decreases symptom burden in humans.

    Human trialn = 371

  2. Ruxolitinib decreases symptom burden in humans (vs best available therapy in patients with hydroxyurea-resistant/intolerant PV) (48.7% vs 18.0% achieving >=50% reduction).

    Human trialvs best available therapy in patients with hydroxyurea-resistant/intolerant PVweek 16

Nitrotyrosine

downin mice1

1 study
  1. Ruxolitinib decreases nitrotyrosine in mice (static cold storage).

    Animalsstatic cold storagein histidine-tryptophan-ketoglutarate solutionheart2 hmale and females

More on Nitrotyrosine

SASP-related cytokine release

downin mice1

1 study
  1. Ruxolitinib decreases SASP-related cytokine release in mice (static cold storage; TNF-α reduction only in female hearts).

    Animalsstatic cold storage; TNF-α reduction only in female heartsin histidine-tryptophan-ketoglutarate solutionheart2 hmale and females

Heart contractility

upin mice1

1 study
  1. Ruxolitinib improves heart contractility in mice (static cold storage; compared with HTK alone) (Female developed pressure: 111 ± 17 vs. 44 ± 10%; male: 71 ± 9% vs. 47 ± 18%).

    Animalsstatic cold storage; compared with HTK alonein histidine-tryptophan-ketoglutarate solutionheart2 hmale and females

Autoimmune demyelination

downin mice1

1 study
  1. Ruxolitinib protects against autoimmune demyelination in mice.

    Animals

    Senescent CD4 T cells drive age-associated autoimmunity in mice and humans

    bioRxiv : the preprint server for biologyPreprint

More on Autoimmune demyelination

Bone marrow adiposity

downin mice1

1 study
  1. Ruxolitinib decreases bone marrow adiposity in mice (post-radiotherapy).

    Animalspost-radiotherapymales

Telomere dysfunction

downin mice1

1 study
  1. Ruxolitinib decreases telomere dysfunction in mice (post-radiotherapy).

    Animalspost-radiotherapymales

More on Telomere dysfunction

Hematocrit control

upin humans1

1 study
  1. Ruxolitinib improves hematocrit control in humans (62.0% vs 18.2%).

    Human trialn = 371

All 39

Has ruxolitinib been tested in people?

0 of 348 about aging

Yes: 2 trials and 2 observational studies in people have been published, and 347 trials are registered.

Approved

  • FDA Jakafi

    Nov 16, 2011Polycythemia Vera, Primary Myelofibrosis, Acute Graft Versus Host Disease, Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis, Graft-versus-host Disease, Chronic Graft Versus Host Disease, Steroid-Refractory Acute Graft Versus Host Disease

  • EMA Jakavi

    Aug 23, 2012Myeloproliferative Disorders, Polycythemia Vera, Graft vs Host Disease, Primary Myelofibrosis, Splenomegaly, Acute Graft Versus Host Disease, Chronic Graft Versus Host Disease, Graft -Versus-host-disease, Myelofibrosis

  • FDA Opzelura

    Sep 21, 2021Dermatitis, Atopic, NonSegmental Vitiligo

  • EMA Opzelura

    Apr 19, 2023Vitiligo, Dermatitis, Atopic, Non-segmental Vitiligo

  • FDA Jakafi XR

    May 1, 2026Polycythemia Vera, Primary Myelofibrosis, Acute Graft Versus Host Disease, Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis, Graft-versus-host Disease, Chronic Graft Versus Host Disease, Steroid-Refractory Acute Graft Versus Host Disease

  • EMA Ruxolitinib Viatris

    Sep 18, 2026Primary Myelofibrosis, Polycythemia Vera, Graft vs Host Disease, Splenomegaly, Acute GVHD, Acute Graft Versus Host Disease, Chronic Graft Versus Host Disease, Graft -Versus-host-disease, Myelofibrosis

Repurposing

40 of 88

In trials

  • Leukemia myeloid acute

    Phase 4Active, not recruiting21 trials

  • Safety and Efficacy

    Phase 4Status unknown2 trials

  • Extranodal NK/T-cell lymphoma

    Phase 4Status unknown1 trial

  • Precursor cell lymphoblastic leukemia lymphoma

    Phase 3Completed15 trials

  • Prurigo

    Phase 3Results posted2 trials

  • Macrophage activation syndrome

    Phase 3Status unknown1 trial

40 of 42

Stopped

  • NCT05696392TerminatedAtopic dermatitis

    The study was terminated due to lack of enrollment.

  • NCT03701698TerminatedAcute graft versus host disease

    Participants recruitment failure

  • NCT04377620TerminatedCOVID-19

    Study terminated by sponsor

  • NCT02117479TerminatedPancreatic neoplasms

    The study was terminated early based on the results of the planned interim analysis.

  • NCT02119663TerminatedPancreatic neoplasms

    The safety committee found no safety issues but recommended halting the study based on a lack of efficacy in a similar trial. The sponsor terminated the trial.

  • NCT02962388TerminatedEssential thrombocythemia

    not enough recruitment

All 25

Who is developing ruxolitinib?

3 companies: Incyte, Novartis Pharmaceuticals and AbbVie.

Companies
  • IncytePhase 4atopic dermatitis, hidradenitis suppurativa
  • Novartis PharmaceuticalsPhase 4steroid refractory acute graft versus host disease, graft vs. host disease
  • AbbViePhase 3myelofibrosis, myeloproliferative neoplasm

Trial sponsors

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    In male mice after radiotherapy, ruxolitinib reduces bone marrow adiposity, telomere dysfunction and bone damage; a preprint also reports protection against autoimmune demyelination in mice with CIDP-like disease. Four findings span two independent labs without replication of the same change; 57 registered trials ended over a year ago without posted results or a citing paper.

  2. Summary written from the findings.

Latest

Dec 2025: 1Jan 2026: 2Feb 2026: 1Mar 2026: 3Apr 2026: 0May 2026: 2Jun 2026: 1Jul 2026: 2Aug 2026: 3Sep 2026: 1Oct 2026: 2Nov 2026: 018 papers in 12 months
Journal of Translational Medicine

Ruxolitinib reduces retinal blood vessel leakage in rats

In Brown-Norway rats with laser-induced eye damage, the drug reduced abnormal blood vessel area and accelerated the recovery of retinal function.In Brown-Norway rats with laser-induced eye damage, the drug reduced abnormal blood vessel area and accelerated the recovery of retinal function.

Rat studyEye
Neurotherapeutics

Enzyme-blocking drugs linked to lower Parkinson disease risk

Among 11 drugs examined, sorafenib prescription fills were linked to a relative risk of 0.43 for Parkinson disease compared with no fills for that drug.Among 11 drugs examined, sorafenib prescription fills were linked to a relative risk of 0.43 for Parkinson disease compared with no fills for that drug.

Case-control studyParkinson's disease
Research Square

Delayed drug delivery improved bone repair in aged mice

In an experiment with six aged female mice per group, grafts that delayed ruxolitinib release produced more new bone after nine weeks.In an experiment with six aged female mice per group, grafts that delayed ruxolitinib release produced more new bone after nine weeks.

Preprint: mouse studyBones and joints

See all 36 papers on ruxolitinib